New drug hopes to ease breathing and heart strain in lung disease patients
NCT ID NCT06475781
First seen Jun 27, 2026 · Last updated Aug 12, 2026 · Updated 4 times
Summary
This study tests a drug called mirivadelgat in people with high blood pressure in the lungs caused by lung scarring (PH-ILD). The goal is to see if it improves blood flow in the lungs, exercise ability, and overall well-being. About 126 participants will take the drug or a placebo daily for 12 weeks, with regular checkups.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GROUP 3 PULMONARY HYPERTENSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Chang Gung Memorial Hospital - Linkou Branch
RECRUITINGTaoyuan City, Taiwan, Taiwan
-
Hualien Tzu Chi Hospital
RECRUITINGHualien City, Taiwan, 970, Taiwan
-
Kaohsiung Medical University Chung-Ho Memorial Hospital
RECRUITINGKaohsiung City, Taiwan, Taiwan
-
Kaohsiung Veterans General Hospital
RECRUITINGKaohsiung City, 813, Taiwan
-
MacKay Memorial Hospital
RECRUITINGTaipei, 104, Taiwan
-
National Cheng Kung University Hospital
RECRUITINGTainan, Taiwan, 704, Taiwan
-
National Taiwan University Hospital
RECRUITINGTaipei, Taiwan, 100225, Taiwan
-
Taichung Veterans General Hospital
RECRUITINGTaichung, Taiwan, 407219, Taiwan
-
Taipei Veterans General Hospital
RECRUITINGTaipei, Taiwan, 11217, Taiwan